<DOC>
	<DOCNO>NCT00333515</DOCNO>
	<brief_summary>The purpose placebo-controlled study evaluate safety , tolerability pharmacokinetics single dose regimen human butyrylcholinesterase ( HuBChE ) healthy adult 3 ascend dosage level administer IV . HuBChE , occur naturally human plasma , evaluate prophylaxis treatment event exposure chemical nerve agent ( employed chemical warfare act terrorism ) . Volunteers dosage cohort randomize treatment HuBChE active drug normal saline placebo 3:1 ratio . The volunteer remain study 90 ( +/- 7 ) day . For first 3 day follow dose administration , remain clinical trial site inpatient closely monitor patient safety . Afterwards , return trial site ( pre-determined interval ) outpatients 8 visit , patient safety assess .</brief_summary>
	<brief_title>Pharmacokinetic ( PK ) Safety Study Plasma-derived Human Butyrylcholinesterase Administered Intravenously</brief_title>
	<detailed_description />
	<criteria>The volunteer 18 55 year age ( inclusive ) time administration HuBChE . The volunteer good health determine Investigator ( Study Doctor ) medical history physical examination . The volunteer clinical chemistry , hematology , coagulation , urinalysis laboratory value within acceptable range deem clinically insignificant Principal Investigator ( PI ) Project Medical Monitor . The volunteer normal electrocardiogram ( ECG ) one clinically insignificant finding deem PI . The volunteer willing blood sample store future HuBChE research study . The volunteer sign Informed Consent form ( ICF ) sign Health Insurance Portability Accountability Act ( HIPAA ) authorization form . The volunteer agree donate blood trial least 2 month follow 90 day study visit . The volunteer willing comply requirement protocol postinfusion Day 90 ( ± 7 day ) visit . Female volunteer must nonchildbearing potential ( i.e. , surgically sterilize postmenopausal ) , must pregnant ( indicated negative urine pregnancy test within 1 day prior HuBChE administration ) nursing , must use two type acceptable form Food Drug Administration ( FDA ) approve birth control method , include : Progesterone hormonal type birth control ( implant birth control pill ) intrauterine device ( IUD ) additional barrier type birth control measure ( i.e. , condom , diaphragm , cervical cap , etc . ) period begin 30 day HuBChE administration completion study . Completion study define complete acute phase study ( Day 45 [ ± 3 day ] visit ) . The volunteer demonstrate predisposition thrombus formation determine past medical history , family history . The volunteer history anaphylactoid reaction serious adverse reaction blood product . The volunteer history allergic reaction procainamide metabolite , paminobenzoic acid . The volunteer diagnose alcohol drug abuse within 12 month prior study screen offer history alcohol drug abuse within 12 month prior screen . The volunteer positive result urine drug screen test common substance abuse , amphetamine , barbiturate , benzodiazepine , cocaine , opiates , cannabinoids . ( If positive screen , confirmatory test shall perform applicable . ) The volunteer previous diagnosis serious psychiatric disorder . For purpose , serious psychiatric disorder define illness require hospitalization within previous 12 month ; routine administration one medication control anxiety , mood sleep disorder ; history suicide attempt . The volunteer receive blood product immune globulin previous six month . The volunteer donate blood within 56 day prior receipt study product ( Day 0 ) . The volunteer deficiency immunoglobulin A ( IgA ) determine screen . The volunteer current past medical history condition , opinion PI and/or Project Medical Monitor ( PMM ) , might place risk participate study . Personal family history ( first degree relative ) significant neuromuscular disease ( determined PI ) . Female volunteer pregnant ( must negative urine pregnancy test within 1 day receipt HuBChE ) , lactate , unwilling use 2 type acceptable FDAapproved form contraception time screen completion Day 45 ( ± 1 day ) study visit . Current use , receipt within previous 14 day , intent use 14 day receive drug product drug may metabolize , inhibit , otherwise affected BChE . The volunteer clinically significant abnormality ECG . The volunteer laboratory value outside acceptable range clinically significant assessed Investigator and/or PMM . The volunteer test positive HIV , HCV , HBV screening . The volunteer acute illness , evidence significant active infection , evidence systemic disease time enrollment opinion PI would place volunteer unacceptable risk injury . The volunteer temperature &gt; 100.4°F time dose administration . The volunteer occupational responsibility would prevent completion participation study . The volunteer currently use tobacco product . Participants clinical trail past 60 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Chemical nerve agent intoxication</keyword>
</DOC>